SEC Form 4 · accession 0001764013-26-000082
Immunovant, Inc. · IMVT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Van Tuyl
Officer — Chief Legal Officer
Period of report
Jul 8, 2026
Accepted (ET)
Jul 10, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001764013
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 8, 2026 | S | 1,143 | $39.53 | D | 179,454 | D | |
| Common StockF1,F3 | Jul 8, 2026 | S | 63 | $39.99 | D | 179,391 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On April 1, 2025, the holder was granted 50,787 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 3,174 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.